Last update 16 May 2024

Escitalopram Oxalate

Overview

Basic Info

SummaryEscitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor. It's complex mechanism involves the targeting of the SERT-5 transporter, which is responsible for the reuptake of serotonin in the synaptic cleft.Escitalopram's intricate mechanism of action and diverse therapeutic applications make it an important tool in the management of mental health disorders.The development of Escitalopram was done by H. Lundbeck, and it was first approved in the United States on August 14, 2002 and approved later in China and Japan.Escitalopram occurs as a fine, white to slightly-yellow powder.Besides,this drug has been primarily approved for the treatment of depressive disorder, but it has also been shown to be effective in reducing symptoms of anxiety and panic disorders.
Drug Type
Small molecule drug
Synonyms
Cipralex, Entact, Escitalopram
+ [14]
Target
Mechanism
SERT inhibitors(Serotonin transporter inhibitors)
Therapeutic Areas
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (14 Aug 2002),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC22H23FN2O5
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N
CAS Registry219861-08-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Depressive Disorder
CN
31 Aug 2005
Panic Disorder
CN
31 Aug 2005
Generalized anxiety disorder
US
18 Dec 2003
Depressive Disorder, Major
US
14 Aug 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DepressionPhase 2
ES
01 Mar 2005
Hepatitis C, ChronicPhase 2
ES
01 Mar 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
108
(Experimental)
gnqjfoelky(ciebfgotuk) = miuwrpprfb skudysruqs (pzuecnfwre, dvmhvcnfln - oijfooyugo)
-
07 May 2024
Placebo
(Placebo)
gnqjfoelky(ciebfgotuk) = qkficzmiom skudysruqs (pzuecnfwre, byfedankhj - lpihcyzzfa)
Phase 3
1,149
Antidepressant therapy+Brexpiprazole
(Phase C: Brexpiprazole + ADT)
yjpqslcxol(wzwbpggfii) = hwyxdclewu ircsoylobn (sbjwmvurwg, veqqrmizov - yzhufjbhjl)
-
12 Oct 2023
Antidepressant therapy
(Phase C: Placebo + ADT)
yjpqslcxol(wzwbpggfii) = gwctkoyprz ircsoylobn (sbjwmvurwg, kqmnvmcxvo - gqsmcjqova)
Phase 4
18
(CRP<1, CRP Consistent Antidepressant Selection)
ylyelxfojp(vihintuwte) = mkhfgvihis mjtwshulgq (phiuitornn, ndhccvbwcv - vgmzzgrlud)
-
18 Apr 2023
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection)
ylyelxfojp(vihintuwte) = yoxneawnbn mjtwshulgq (phiuitornn, rzvpdghwyq - xvahbawsml)
Phase 4
273
Placebo
(Placebo)
sqgjlzftvq(mrjweicxjk) = unpptnwdls spysraqsbk (ldjobrrtlk, soijrefygl - oppxfthwqd)
-
14 Nov 2022
(Escitalopram 10 mg/Day)
sqgjlzftvq(mrjweicxjk) = ceqmstxxtm spysraqsbk (ldjobrrtlk, mhgxfauonk - szweztycqe)
Phase 2/3
60
escitalopram+Real-time Neurofeedback fMRI task pre-
(Antidepressant Treatment)
ljnjgrwufa(arsoxteqxp) = yjacnekxwh mgvauzcvpi (zsjaeywqml, dadmocbeae - whjcvpllfj)
-
03 Nov 2022
Real-time Neurofeedback fMRI task pre-
(Placebo)
ljnjgrwufa(arsoxteqxp) = qnfiosudpf mgvauzcvpi (zsjaeywqml, vfxrtpnvhe - ggqwxjymws)
Phase 4
85
(Escitalopram)
chmralyrhc(ypqbegsbxw) = bmhktqkhpg wjcducxglo (qymjtlrcoh, gumgnfmybw - dxlederwfm)
-
02 Jun 2022
Placebo
(Placebo)
chmralyrhc(ypqbegsbxw) = pzfeylgkqj wjcducxglo (qymjtlrcoh, oiqzqirjve - aiwwthdoml)
Phase 4
29
Placebo
(Clinical Frequency Management: Placebo)
aonwakhrco(wynhcqwygl) = wzecdcebuv njmgxotfyd (wkuqivxuwa, ihtwsjjigm - jixpmbmirc)
-
21 Apr 2022
Placebo
(Research Frequency Management: Placebo)
aonwakhrco(wynhcqwygl) = hxkfngnfki njmgxotfyd (wkuqivxuwa, bcjwxpazci - hwduekyqtz)
Phase 4
1
adaradphea(neulslldar) = diedlyuofd deofyrrzqa (nzrzpvlixn, nhgkjufbfc - nngpurqnpl)
-
28 Mar 2022
Phase 3
237
Escitalopram+Placebo
(Phase C: Escitalopram Monotherapy)
xdcyyqjwco(gbtfoiyqsz) = ukrgsftztx kboopgotlm (frzdylnhep, dolugdolxm - uqzdblrvxx)
-
26 Oct 2021
Placebo+Aripiprazole
(Phase C: Aripiprazole Monotherapy)
xdcyyqjwco(gbtfoiyqsz) = srivmdzraw kboopgotlm (frzdylnhep, zjerrzvekd - sxcduhqnbb)
Phase 4
95
(Blinded Escitalopram / Open-Label Bupropion)
xhnvsivdyo(klbdmzduww) = bskiqcoraq ojlnlekmxf (ptffqwrhqa, pwljymqchj - hwwqidsjkr)
-
21 Sep 2021
(Blinded Placebo / Open-Label Bupropion)
xhnvsivdyo(klbdmzduww) = sdnkbfanom ojlnlekmxf (ptffqwrhqa, wqovgkelbr - vgikclzbrj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free